Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec 1;67(4):702-710.
doi: 10.1097/GRF.0000000000000895. Epub 2024 Oct 18.

Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Muhammad Danyal Ahsan  1 , Isabelle R Chandler, Samantha Min, Benjamin Grant, Michelle Primiano, Jamieson Greenwald, Tamar N Soussana, Becky Baltich Nelson, Charlene Thomas, Eloise Chapman-Davis, Ravi N Sharaf, Melissa K Frey
Affiliations
Meta-Analysis

Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Muhammad Danyal Ahsan et al. Clin Obstet Gynecol. .

Abstract

This is a systematic review and meta-analysis evaluating the uptake of cascade genetic testing for hereditary breast and ovarian cancer syndrome. Among 30 studies included for meta-analysis, the uptake of cascade genetic testing was 33% (95% CI 25%-42%), with higher uptake rates among females compared with male relatives, and among first-degree compared with second-degree relatives. These findings indicate suboptimal uptake of cascade genetic testing among people at risk for hereditary breast and ovarian cancer syndrome, representing a missed opportunity for cancer prevention and early detection. There is a need for interventions to improve uptake rates.

PubMed Disclaimer

References

    1. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–490.
    1. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547–1553.
    1. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in brca1 or brca2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22:3971–3981.
    1. National Comprehensive Cancer Network. Guideline: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024). 2024.
    1. Committee on Gynecologic P. ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018;131:e31–e34.

MeSH terms